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The current standard of care for patients with multiple
myeloma involves treatment with proteasome inhibitors such
as bortezomib and immunomodulatory drugs such as
lenalidomide.1,2 With the recent advances in treatment, the 5-
and 10-year relative survival rates for multiple myeloma are
now 40% and 21%, respectively.3 However, most patients
with multiple myeloma will relapse several times during the
course of their disease.4 There are few established treatments
available for those who have exhausted novel agents. The
median overall survival for patients in whom bortezomib or
immunomodulatory drugs have failed is only 9 months,
demonstrating the clear, unmet need for further treatment
options for such patients.4
The chromosomal aberrations  del(17p) and t(4;14) (found in
approximately 11% and 14% of multiple myeloma patients,
respectively) are associated with an adverse prognosis, reduc-
ing median event-free survival from diagnosis to 20.6 months
(versus 36.5 months; P<0.001) and 15 months (versus 35
months; P<0.001), respectively.5,6 The presence of t(4;14) was
also found to predict shorter survival in patients with
advanced relapsed or refractory disease treated with lenalido-
mide and dexamethasone (9.4 versus 15.4 months; P=0.005).7
The (4;14) translocation results in increased expression of the
oncogenes fibroblast growth factor receptor 3 (FGFR3) and
multiple myeloma set domain (MMSET).8-10 The chromosomal
abnormality del(17p) is frequently associated with mutations
in the TP53 gene or alterations in the p53 pathway.11 Few stud-
ies have analyzed the impact of these cytogenetic features or
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Patients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel
agents have limited treatment options and short expected survival. del(17p) and t(4;14) are correlated with shortened
survival. The phase 3 MM-003 trial demonstrated significant progression-free and overall survival benefits from
treatment with pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone among
patients in whom bortezomib and lenalidomide treatment had failed. At an updated median follow-up of 15.4
months, the progression-free survival was 4.0 versus 1.9 months (HR, 0.50; P<0.001), and median overall survival
was 13.1 versus 8.1 months (HR, 0.72; P=0.009). Pomalidomide plus low-dose dexamethasone, compared with high-
dose dexamethasone, improved progression-free survival in patients with del(17p) (4.6 versus 1.1 months; HR, 0.34;
P <0.001), t(4;14) (2.8 versus 1.9 months; HR, 0.49; P=0.028), and in standard-risk patients (4.2 versus 2.3 months; HR,
0.55; P<0.001). Although the majority of patients treated with high-dose dexamethasone took pomalidomide after
discontinuation, the overall survival of patients treated with pomalidomide plus low-dose dexamethasone or high-
dose dexamethasone was 12.6 versus 7.7 months (HR, 0.45; P=0.008) in patients with del(17p), 7.5 versus 4.9 months
(HR, 1.12; P=0.761) in those with t(4;14), and 14.0 versus 9.0 months (HR, 0.85; P=0.380) in standard-risk subjects.
The overall response rate was higher in patients treated with pomalidomide plus low-dose dexamethasone than in
those treated with high-dose dexamethasone both among standard-risk patients (35.2% versus 9.7%) and those with
del(17p) (31.8% versus 4.3%), whereas it was similar in patients with t(4;14) (15.9% versus 13.3%). The safety of
pomalidomide plus low-dose dexamethasone was consistent with initial reports. In conclusion, pomalidomide plus
low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma and del(17p) and/or
t(4;14). This study is registered at ClinicalTrials.gov as NCT01311687 and with EudraCT as 2010-019820-30.
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ABSTRACT
other baseline characteristics specifically in advanced
relapsed/refractory multiple myeloma.4,12,13
Pomalidomide is a distinct immunomodulatory drug
with direct antimyeloma, stromal support–inhibitory, and
immunomodulatory effects.14 The open-label, randomized
phase 2 MM-002 trial reported an overall response rate of
33% to pomalidomide + low-dose dexamethasone
(LoDEX), with a median progression-free survival of 4.2
months and median overall survival of 16.5 months. These
results were consistent even in patients who were refracto-
ry to lenalidomide as the most recent line of prior therapy.15
Additionally, pomalidomide  + LoDEX was effective in
patients presenting with the cytogenetic abnormalities
del(17p) and/or t(4;14).15 Favorable results with pomalido-
mide + LoDEX in patients with del(17p) were also seen in
the IFM 2010-02 trial.16 The international, multicenter,
open-label, randomized, phase 3 trial MM-003 compared
pomalidomide + LoDEX (n=302) with high-dose dexa -
methasone (HiDEX; n=153) treatment in patients with
multiple myeloma refractory to their last prior treatment in
whom bortezomib and lenalidomide had previously failed.
Initial results at a median follow-up of 10 months showed
significant improvements in progression-free survival [(4.0
versus 1.9 months; hazard ratio (HR), 0.48; P<0.0001)] and
overall survival (12.7 versus 8.1 months; HR, 0.74;
P=0.0285) with pomalidomide + LoDEX, with similar effi-
cacy across various populations of patients, including those
refractory to lenalidomide as last prior treatment.17 The
most common grade 3/4 adverse events reported were
hematologic (neutropenia, anemia, and thrombocytope-
nia).
This updated analysis of the MM-003 trial presented
here is based on a median follow-up of 15.4 months.
Analyses of baseline characteristics predictive of long-term
benefit and assessments of the impact of high-risk cytoge-
netic abnormalities are also reported.
Methods
Study design and patients
A full description of the study design, inclusion and exclusion
criteria, and treatment protocol has been published elsewhere.17
Briefly, MM-003 was an open-label, randomized, phase 3 trial
conducted in 93 centers in the European Union, Russia,
Switzerland, Australia, Canada, and the USA. Patients enrolled
had to have refractory or relapsed and refractory multiple myelo-
ma treated with two or more prior antimyeloma regimens, have
been refractory to their last prior treatment, failed prior treatment
with bortezomib and lenalidomide (following ≥2 previous consec-
utive cycles of each, alone or in combination), and have received
adequate prior alkylator therapy. Failure of bortezomib and
lenalidomide therapy was defined as progressive disease on or
within 60 days of completing treatment, progressive disease ≤6
months after achieving a partial response, or intolerance when
achieving no more than a minimal response (bortezomib only).
Additional details regarding the selection of patients have been
described elsewhere.17
All patients provided written informed consent to participate in
the study, which was approved by institutional review boards or
independent ethics committees at all participating centers and per-
formed in accordance with the Declaration of Helsinki and the
International Conference on Harmonisation Guidelines on Good
Clinical Practice. This trial is registered with ClinicalTrials.gov
(NCT01311687) and EudraCT (2010-019820-30). All authors and
the sponsor were involved in the data collection, analysis, review,
and interpretation and writing of the report.
A total of 455 patients were randomized in a 2:1 ratio to receive
28-day cycles of pomalidomide (4 mg/day orally on days 1-21) +
LoDEX (40 mg/day orally on days 1, 8, 15, and 22) or HiDEX (40
mg/day orally on days 1-4, 9-12, and 17-20). In both arms of the
study, dexamethasone was administered at a dose of 20 mg/day
for patients aged ≥75 years. Treatment was continued until pro-
gression or unacceptable toxicity. Thromboprophylaxis, consist-
ing of the physician’s choice of low-dose aspirin or low-molecu-
lar-weight heparin, was required for all patients who received
pomalidomide and those at high risk of developing thrombosis.
Assessments and statistical analyses
The primary endpoint was progression-free survival and sec-
ondary endpoints included overall survival, rate of overall
responses defined by International Myeloma Working Group
(IMWG)18 and European Group for Blood and Marrow Transplant
(EBMT)19 criteria, time to progression, duration of response, dura-
tion of treatment, safety, and quality of life. Progression-free sur-
vival and response were based on investigator assessment. For
cytogenetic analyses, samples were collected at the time of
screening the patients and analyzed by a central laboratory, as
described previously.20 Briefly, enrichment of CD138+ plasma cells
was followed by interphase fluorescence in situ hybridization
(FISH) for TP53 deletion [del(17p)] and/or fibroblast growth factor
receptor 3/immunoglobulin heavy locus gene rearrangement
[t(4;14)]. Any detectable presence of mutation was considered a
positive result.
Progression-free survival, overall survival, and duration of
response were estimated using the Kaplan-Meier product-limit
method and compared between treatment groups using log-rank
tests stratified by age, disease population, and number of prior
antimyeloma therapies. Overall response rate was compared
between treatment arms using the Fisher exact test. Progression-
free survival and overall survival for patients within each treat-
ment arm were analyzed by cytogenetic abnormality status using
an unstratified log-rank test. Patients in the pomalidomide +
LoDEX arm who survived >12 or ≤12 months were descriptively
compared with respect to demographics and baseline characteris-
tics to identify potential factors that may contribute to longer sur-
vival. Then, these identified potential factors were used in a Cox
regression model selection process for overall survival in all sub-
jects in the pomalidomide + LoDEX arm. The forward selection
method was used to identify significant factors.
Results
Patients’ characteristics
The data cutoff for this report was September 1, 2013, for
a median follow-up of 15.4 months. The treatment arms
were well balanced. Patients were heavily pretreated, with a
median of five lines of prior therapy in both arms (Table 1).
A total of 225 patients (75%) treated with pomalidomide +
LoDEX and 107 patients (70%) treated with HiDEX had
evaluable cytogenetics. Chromosomal abnormalities were
balanced between arms: 15% of patients in each treatment
arm were positive for del(17p) and 15% (pomalidomide +
LoDEX) and 10% (HiDEX) were positive for t(4;14).
Updated survival (intent-to-treat population)
With extended follow-up, the median progression-free
survival remained significantly longer with pomalidomide
+ LoDEX versus HiDEX (4.0 versus 1.9 months; HR, 0.50;
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P<0.001). The median overall survival was also significant-
ly longer with pomalidomide + LoDEX versus HiDEX
(Figure 1; 13.1 versus 8.1 months; HR, 0.72; P=0.009). This
overall survival advantage was observed despite 85
patients (56%) on the HiDEX arm receiving subsequent
pomalidomide-based treatment. Multivariate analysis of
the pomalidomide + LoDEX treatment arm identified sev-
eral baseline characteristics significantly associated with
longer overall survival: normal lactate dehydrogenase level,
higher level of hemoglobin or platelets, lower Eastern
Cooperative Oncology Group (ECOG) performance status,
and absence of plasmacytoma (Table 2). Normal lactate
dehydrogenase level, higher platelet count, and lower
ECOG performance status were also significantly associat-
ed with longer duration of response.
Safety
The updated safety profile of this analysis was consistent
with that reported in the original publication (Table 3).17
The most common grade 3/4 adverse events were neu-
tropenia (49% versus 17%), anemia (33% versus 39%), and
infections (33% versus 24%) for the pomalidomide +
LoDEX versus HiDEX safety populations, respectively. The
rates of discontinuation due to adverse events were low
considering the heavily pretreated condition of this popu-
lation of patients and were comparable between the two
treatment arms (9% versus 10%).  In the 54 pomalidomide
+ LoDEX patients who were treated for 1 year or longer,
the most frequent grade 3/4 adverse events were neutrope-
nia (52%) and infections (43%). These patients experi-
enced anemia and thrombocytopenia notably less fre-
quently (both 9%) compared with the pomalidomide +
LoDEX safety population. 
Cytogenetic subanalyses
A significant progression-free survival benefit of poma-
lidomide + LoDEX treatment versus HiDEX was observed
in all cytogenetic subgroups (Table 4): del(17p) (4.6 versus
1.1 months; HR, 0.34; P<0.001), t(4;14) (2.8 versus 1.9
months; HR, 0.49; P=0.028), and standard-risk (4.2 versus
2.3 months; HR, 0.55; P<0.001). The overall survival of
patients treated with pomalidomide + LoDEX was longer
than that of patients treated with HiDEX in all groups: the
difference was statistically significant for patients with
del(17p) (12.6 versus 7.7 months; HR, 0.45; P=0.008)  and
showed a trend for those with t(4;14) (7.5 versus 4.9
months; HR, 1.12; P=0.761) and standard-risk patients
(14.0 versus 9.0 months; HR, 0.85; P=0.380). The overall
survival benefit was achieved despite high numbers of
HiDEX patients subsequently receiving pomalidomide:
46% of del(17p)/t(4;14) and 64% of standard-risk patients.
An analysis of the impact of del(17p) and t(4;14) within
the HiDEX arm showed that these cytogenetic abnormali-
ties are associated with worsened outcomes. The median
progression-free survival was reduced from 2.3 months for
standard-risk patients to 1.1 months for those with
del(17p) or 1.9 months for those with t(4;14) (Figure 2B;
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Table 1. Patients’ baseline characteristics.
Characteristic                                        POM + LoDEX            HiDEX
                                                                   (n = 302)             (n = 153)
Age, median years (range)                               64 (35-84)              65 (35-87)
Time from initial diagnosis,                           5.3 (0.6-30.0)         6.1 (0.9-21.1)
median, years (range)
ECOG performance status, n (%)                                                             
0-1                                                                          248 (82)                  122 (80)
2-3                                                                           52 (17)                    28 (18)
Missing                                                                  2 (< 1)                      3 (2)
ISS stage, n. (%)                                                                                            
I-II                                                                          196 (65)                   92 (60)
III                                                                            92 (30)                    53 (35)
Missing                                                                   14 (5)                       8 (5)
Creatinine clearance < 60 mL/min, n (%)      95 (31)                    59 (39)
N. of previous treatments, median (range)  5 (2-14)                   5 (2-17)
Refractory to bortezomib, %                                 79                             79
Refractory to lenalidomide, %                              95                             92
Refractory to lenalidomide                                   75                             74
and bortezomib, %
Evaluable for cytogenetics, n (%)                    225 (75)                  107 (70)
del(17p)                                                                44 (15)                    23 (15)
t(4;14)                                                                    44 (15)                    15 (10)
del(17p) and t(4;14)                                            11 (4)                       3 (2)
ECOG: Eastern Cooperative Oncology Group; HiDEX: high-dose dexamethasone; ISS:
International Staging System; LoDEX: low-dose dexamethasone; POM: pomalidomide.
Table 2. Multivariate Cox proportional hazards analysis of baseline
characteristics predictive of overall survival and duration of response
in patients treated with pomalidomide + LoDEX.
Model parameter                                            HR                     P-valuea
Overall survival
Baseline LDH > 1.5 × ULN                                 0.471                          0.003
Baseline hemoglobin ≥ 10 g/dL                         0.611                          0.003
ECOG PS 0/1-2                                                        0.668                          0.022
Presence of plasmacytoma                                 2.096                          0.002
Baseline platelets ≥ 75 × 109/L                          0.538                        < 0.001
Duration of responseb
Baseline LDH > 1.5 × ULN                                 0.263                          0.029
ECOG PS 0/1-2                                                        0.520                          0.027
Baseline platelets ≥ 75 × 109/L                          0.313                          0.001
aBased on the Cox proportional hazard model comparing the hazard functions associ-
ated with the model parameter. bSubjects with at least partial response based on inves-
tigator assessment using IMWG criteria. ECOG: Eastern Cooperative Oncology Group;
HR: hazard ratio; LDH: lactate dehydrogenase; LoDEX: low-dose dexamethasone; PS:
performance status; ULN: upper limit of normal.
Figure 1. Kaplan-Meier curve of overall survival (OS) for the intent-to-
treat population. HiDEX: high-dose dexamethasone; HR: hazard
ratio; LoDEX: low-dose dexamethasone; POM: pomalidomide.
P=0.023 and 0.161, respectively). The median overall sur-
vival was similarly reduced, from 9.0 months for standard-
risk patients to 7.7 months for those with del(17p) or 4.9
months for patients with t(4;14) (Figure 3B; P=0.019 and
0.516, respectively).
Among the patients treated with pomalidomide +
LoDEX, the outcomes in those with del(17p) are similar to
those in patients with standard-risk, with a progression-
free survival of 4.6 months versus 4.2 months (HR, 0.99;
P=0.942) and overall survival of 12.6 months versus 14.0
months (HR, 1.22; P=0.358). The presence of t(4;14) was a
significant negative predictor, shortening progression-free
survival to 2.8 months (HR, 1.50; P=0.023 versus standard-
risk) and overall survival to 7.5 months (HR, 1.72; P=0.008
versus standard-risk).
Response to pomalidomide + LoDEX treatment differed
dramatically between cytogenetic risk groups (Table 5).
Patients with del(17p) treated with pomalidomide +
LoDEX had an overall response rate similar to that in
patients with standard cytogenetic risk (31.8% in compar-
ison with 35.1%), whereas the response rate was much
lower in patients with t(4;14) (15.9%). The rate of response
to HiDEX was somewhat lower in patients with del(17p)
(4.3%) than in patients with standard cytogenetic risk
(9.7%), while patients with t(4;14) were slightly more like-
ly to respond (13.3%). Response to HiDEX was numerical-
ly lower than to pomalidomide + LoDEX in each cytoge-
netic risk group.
Subsequent treatments
Approximately half (33/63) of the patients treated with
pomalidomide + LoDEX who progressed following
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Table 3. Most commonly reported grade 3/4 adverse events for safety popula-
tions and patients treated with pomalidomide (POM) + LoDEX for 1 year or
more.
                                                    POM + LoDEX           HiDEXa          POM + LoDEX
                                                           safety                 safety               ≥ 1 year 
                                                       population           population        of treatment
                                                        (n = 300)            (n = 150)            (n = 54)
Grade 3-4 hematologic AE, n. (%)                                                                               
Neutropenia                                           146 (49)                   26 (17)                  28 (52)
Febrile neutropenia                               28 (9)                       0 (0)                     9 (17)
Anemia                                                      98 (33)                    58 (39)                    5 (9)
Thrombocytopenia                                 67 (22)                    39 (26)                    5 (9)
Leukopenia                                               27 (9)                       5 (3)                      5 (9)
Grade 3-4 non-hematologic AE, n. (%)                                                                       
Infections                                                 98 (33)                    37 (24)                  23 (43)
Pneumonia                                            42 (14)                     12 (8)                   11 (20)
Bone pain                                                  22 (7)                       7 (5)                      4 (7)
Fatigue                                                       16 (5)                       9 (6)                      4 (7)
Asthenia                                                     11 (4)                      10 (7)                     1 (2)
Glucose intolerance                               12 (4)                      11 (7)                     2 (4)
Discontinuation due to AE, n (%)          28 (9)                     16 (11)                    2 (4)
aMay have received POM-based treatment following crossover. AE: adverse event; HiDEX: high-dose
dexamethasone; LoDEX: low-dose dexamethasone; POM: pomalidomide.
Table 4. Progression-free and overall survival by cytogenetic risk group.
del(17p) t(4;14) Standard risk
POM + LoDEX HiDEX POM + LoDEX HiDEX POM + LoDEX HiDEX
(n = 44) (n = 23) (n = 44) (n = 15) (n = 148) (n = 72)
Median PFS, months 4.6 1.1 2.8 1.9 4.2 2.3
HR (P-value) 0.34 (<0.001) 0.49 (0.028) 0.54 (<0.001)
Median OS, months 12.6 7.7 7.5 4.9 14.0 9.0
HR (P-value) 0.45 (0.008) 1.12 (0.761) 0.85 (0.380)
HiDEX: high-dose dexamethasone; HR: hazard ratio; LoDEX: low-dose dexamethasone; OS: overall survival; PFS: progression-free survival; POM: pomalidomide.
Figure 2. Kaplan-Meier curves of progression-free survival by cytogenetic risk groups for patients treated with (A) POM + LoDEX and (B) HiDEX.
aLog-rank P vs. standard risk. HiDEX: high-dose dexamethasone; HR: hazard ratio; LoDEX: low-dose dexamethasone; PFS: progression-free sur-
vival; POM: pomalidomide.
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achievement of a partial response or better were treated
with at least one subsequent antimyeloma therapy. The
median time from progression to next therapy was 1.8
months (range, 0.02-7.8 months). The most common treat-
ment regimens were bortezomib (30%), lenalidomide
(21%), and thalidomide (15%); a wide variety of therapies
were used demonstrating that a standard of care is not well
established for these patients with advanced disease.
Further survival was generally short, with only half (32/63)
surviving 6 months following progression on pomalido-
mide + LoDEX. 
Discussion
MM-003 was the first randomized phase 3 clinical trial in
refractory or relapsed and refractory multiple myeloma
patients who had failed therapy with bortezomib and
lenalidomide. This updated analysis with 15.4 months of
follow-up confirmed the previously reported overall sur-
vival benefit with pomalidomide + LoDEX compared with
HiDEX (median 13.1 versus 8.1 months; P=0.009).17
Importantly, with the extended follow-up, the Kaplan-
Meier overall survival curves continued to diverge in favor
of pomalidomide + LoDEX, even though 56% of patients
randomized to the HiDEX arm subsequently received
pomalidomide-based therapy. These results support early
use of pomalidomide + LoDEX following exhaustion of
bortezomib- and lenalidomide-based options.17 In this long-
term follow-up, the median overall survival of 13.1 months
in patients treated with pomalidomide + LoDEX is consis-
tent with that recently reported with pomalidomide +
LoDEX in the MM-002 trial (16.5 months),15 compares
favorably with historical controls (9 months),4 and is similar
to that reported with carfilzomib (15.6 months)21 in compa-
rable populations of patients. 
The updated safety profile of pomalidomide + LoDEX is
consistent with that reported in the initial MM-003 publica-
tion and previous trials.15,17,22 The extended data demon-
strate that adverse events are manageable after long-term
treatment with pomalidomide + LoDEX. Patients who con-
tinue treatment for 1 year or longer exhibit notably lower
rates of grade 3/4 anemia and thrombocytopenia, which is
consistent with the finding that higher hemoglobin and
platelet levels were associated with longer survival in mul-
tivariate analysis. 
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Table 5. Response to treatment (IMWG criteria).
POM + LoDEX HiDEX
Standard risk del(17p) t(4;14) Standard risk del(17p) t(4;14)
(n = 148) (n = 44) (n = 44) (n = 72) (n = 23) (n = 15)
ORR (≥PR), % 35.2 31.8 15.9 9.7 4.3 13.3
Stringent complete response 0.7 0 0 0 0 0
Complete response 0.7 0 0 0 0 0
VGPR 5.4 6.8 2.3 1.4 0 0
Partial response 28.4 25.0 13.6 8.3 4.3 13.3
Stable disease 51.4 50.0 63.6 63.9 34.8 33.3
Median DOR, monthsa 7.5 4.2 3.7 9.4 4.4 NE
aSubjects with at least partial response based on investigator assessment using IMWG criteria. DOR: duration of response; HiDEX: high-dose dexamethasone; IMWG: International
Myeloma Working Group; LoDEX: low-dose dexamethasone; NE: not estimable; ORR: overall response rate; POM: pomalidomide; PR: partial response; VGPR: very good partial
response.
Figure 3. Kaplan-Meier curves of overall survival (OS) by cytogenetic risk groups for patients treated with (A) POM + LoDEX and (B) HiDEX. aLog-
rank P vs. standard risk. HiDEX: high-dose dexamethasone; HR: hazard ratio; LoDEX: low-dose dexamethasone; POM: pomalidomide.
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Features associated with worse prognosis have not been
thoroughly evaluated in advanced relapsed/refractory mul-
tiple myeloma. A study conducted by the IMWG found
that higher β2-microglobulin and lower serum albumin lev-
els correlated with poorer prognosis in a multivariate
model.4 Multivariate analysis of patients treated with
pomalidomide + LoDEX within MM-003 showed that nor-
mal lactate dehydrogenase level, higher hemoglobin and
platelet levels, lower ECOG performance status, and
absence of plasmacytoma were significantly associated
with longer survival and that normal lactate dehydrogenase
level, higher platelet count, and lower ECOG performance
status were also significantly associated with longer dura-
tion of response. These results confirmed that patients’
characteristics can significantly predict outcomes even in
heavily pretreated patients.
The importance of high-risk cytogenetic features in
advanced relapsed/refractory multiple myeloma has not
been clearly defined. In patients in whom novel agent ther-
apy failed, the IMWG found that t(4;14) at diagnosis con-
tributed to shorter overall survival (HR, 2.14; P=0.086) but
did not find that del(17p) was specifically associated with
shorter overall survival or event-free survival.4 It is impor-
tant to note that limited data regarding cytogenetic status
and FISH results were available for the IMWG study.4 In
particular, information regarding the prognostic value of
cytogenetic status at the time of relapse is currently lacking.
The large advanced relapsed/refractory multiple myeloma
population included in MM-003 makes it a valuable source
to assess the impact of cytogenetic abnormalities. By
Kaplan-Meier analysis, del(17p) was found here to be a sig-
nificant negative predictor of progression-free survival and
overall survival in patients treated without newer agents (ie,
HiDEX); t(4;14) also appeared to predict shortened progres-
sion-free survival and overall survival in these patients,
although the effect was not statistically significant.
This analysis has shown that pomalidomide + LoDEX
was of benefit to patients in the in MM-003 trial regardless
of their cytogenetic risk profile. The progression-free sur-
vival advantages observed with pomalidomide + LoDEX
versus HiDEX in patients with del(17p) or t(4;14) (HR, 0.34
and 0.49, respectively) were similar to those for patients
with standard-risk cytogenetics (HR, 0.55) and the overall
study population (HR, 0.49). The benefits of pomalidomide
+ LoDEX treatment were particularly dramatic in patients
with del(17p), who achieved outcomes statistically indistin-
guishable from standard-risk patients (progression-free sur-
vival: 4.6 versus 4.2 months; P=0.942; overall survival: 12.6
versus 14.0 months; P=0.358). The French IFM 2010-02 trial
of pomalidomide + LoDEX in patients with del(17p) and/or
t(4;14) reported similar findings.16 In this study, the median
time to progression (7.3 versus 2.8 months) and overall sur-
vival (12 versus 9.2 months) appeared longer for patients
with del(17p) than in those with t(4;14).16 However, 75% of
the patients in the MM-003 trial were refractory to both
bortezomib and lenalidomide, whereas 54% were so in the
French trial.17,23
Clinical trials of newer agents suggest that these may
overcome the poor prognosis associated with specific
cytogenetic abnormalities. A recent single-arm trial of
carfilzomib analyzed patients with relapsed/refractory
multiple myeloma and high-risk cytogenetic abnormalities
[defined as del(13) or hypodiploidy by metaphase cytoge-
netic analysis and/or del(17p13), t(4;14), or t(14;16) by
interphase FISH]. In this study, progression-free survival
was not significantly reduced compared with that for stan-
dard-risk patients (median 3.5 versus 4.6 months; P=0.06).12
It is notable that the cytogenetic profile predictive of ben-
efiting from carfilzomib differs from that reported for
pomalidomide + LoDEX.12 The median progression-free
survival and overall survival were shorter in carfilzomib-
treated patients with del(17p) than in patients with t(4;14)
(median progression-free survival, 2.8 versus 4.1 months;
overall survival, 7.0 versus 11.8 months),12 whereas poma-
lidomide + LoDEX–treated patients with del(17p) fared
better than those with t(4;14). The percentages of patients
in the carfilzomib trial positive for del(17p) and t(4;14)
(18% and 11%, respectively) were similar to those in the
MM-003 trial.12
Data regarding the interactions of del(17p) or t(4;14) with
bortezomib treatment are inconsistent. In a small pilot
study of patients with early relapsed or refractory multiple
myeloma, t(4;14) had no impact on response to borte-
zomib treatment, but the effect of del(17p) was not exam-
ined.24 In newly diagnosed multiple myeloma, bortezomib-
containing induction regimens were shown to significantly
improve prognosis and survival for patients with t(4;14)
but not those with del(17p) in IFM 2005-01;25 however, the
HOVON-65 trial showed that the addition of bortezomib
to induction was  beneficial in the presence of del(17p) but
not t(4;14).26 The landmark GIMEMA trial of bortezomib-
thalidomide-dexamethasone induction found that patients
with t(4;14) benefited from the addition of bortezomib, but
the trial did not contain enough del(17p) patients for analy-
sis.27 In contrast, in the Total Therapy 3 protocol, the addi-
tion of bortezomib to thalidomide and dexamethasone
negated the adverse consequences of del(17p) in newly
diagnosed multiple myeloma patients who were low-risk
according to their gene expression profile.28 By comparison,
results from MM-003 and IFM 2010-02 are consistent in
demonstrating that pomalidomide may overcome the poor
outcomes typically associated with del(17p).16 
In conclusion, these updated results for MM-003 confirm
the previous observations that pomalidomide + LoDEX sig-
nificantly improved progression-free survival, overall sur-
vival, and response compared with HiDEX in patients with
refractory or relapsed and refractory multiple myeloma.
Patients with standard-risk cytogenetic profiles or those
with del(17p) or t(4;14) all gain significantly extended pro-
gression-free survival and some degree of overall survival
benefit from pomalidomide + LoDEX vs HiDEX. These
results support the use of pomalidomide + LoDEX as a stan-
dard of care in patients with relapsed/refractory multiple
myeloma following exhaustion of treatment options with
bortezomib and lenalidomide, including patients with the
high-risk cytogenetic abnormalities del(17p) and t(4;14).
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